BioCatalystWatch
KTTAWorkspace / KTTA / OverviewCompany library
Pasithea Therapeutics Corp. logo

Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. (KTTA)

Website

Price
Market cap
Next catalystThroughout 2026PAS-004 — PAS-004-102 advanced solid tumors · Phase 1 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

PAS-004

MEK1 × MEK2

PreINDP1P2P3FilingApproved
Upcoming / outlook

PAS-004

MEK1 × MEK2

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

PAS-004

MEK1 × MEK2

PreINDP1P2P3FilingApproved
Upcoming / outlook

PAS-004

MEK1 × MEK2

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

PAS-004

MEK1 × MEK2

PreINDP1P3FilingApproved

History / paused

α5β1 integrin

PreINDP1P2P3FilingApproved

GlialCAM

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

KTTA PR & News

PR & News

KTTA SEC archive